Aptar Pharma, a global leader in drug delivery systems, has announced an exclusive partnership agreement with Dianosic, a French biotech company, to develop the Active Resorbable Intranasal Scaffold (ARIS) technology platform. The collaboration targets significant unmet needs in treating Chronic Allergic Rhinitis (CAR) and Chronic Rhinosinusitis (CRS) through extended local drug delivery.
Novel "Insert and Forget" Technology
Dianosic's intranasal insert represents a bioresorbable drug delivery solution designed to address patient adherence challenges while maximizing quality of life. The technology aims to deliver drugs locally over extended periods, responding to physician needs for improved efficacy, safety, and ease of use.
The partnership combines Dianosic's cutting-edge clinical innovation and proprietary design with Aptar Pharma's established expertise in nasal drug delivery systems. Under the agreement, Aptar Pharma will invest in Dianosic and participate in its strategic committee while promoting the technology to its pharmaceutical customers.
Expanding into Neurological Applications
Beyond chronic nasal conditions, the collaboration will explore Nose-to-Brain (N2B) drug delivery opportunities, particularly targeting neuropsychiatric and neurodegenerative diseases. This expansion represents a significant advancement in the potential therapeutic applications of the ARIS platform.
"This partnership with Dianosic expands our commitment to deliver innovative and patient-centric solutions by leveraging the potential of intranasal drug-delivery," said Alex Theodorakis, President Aptar Pharma Prescription. "This transformative innovation represents a promising advancement in the management of Chronic Rhinitis and sinusitis, and we are proud to support the ARIS journey to market."
Strategic Market Positioning
Philippe Bastide, CEO and co-founder of Dianosic, emphasized the global reach potential of the partnership: "We are thrilled to join forces with Aptar Pharma as it marks a major step towards making our drug-eluting resorbable Intranasal Scaffold platform accessible worldwide. This alliance supports our commitment to improving intranasal therapeutic options for patients with chronic nasal conditions."
The collaboration leverages Aptar Pharma's comprehensive service portfolio, including Noble's capabilities in human factor studies and patient onboarding, alongside Aptar CSP's active material sciences offerings. Theodorakis noted that this partnership "further reinforces Aptar Pharma's leadership in nasal drug delivery by expanding our innovative portfolio and proposing disruptive solutions to our customers."
The agreement positions both companies to bring a value-added solution to market that enhances patient outcomes while delivering value to pharmaceutical partners through improved treatment adherence and extended drug delivery capabilities.
